Emergent BioSolutions will supply NARCAN® Nasal Spray to Canadian government entities through a new standing offer until 2029.
Quiver AI Summary
Emergent BioSolutions Inc. has been awarded a standing offer by the Government of Canada to supply NARCAN® Nasal Spray, effective from October 1, 2026, to September 30, 2029, with a possible two-year extension. This agreement allows various federal, provincial, and territorial organizations in Canada to easily access NARCAN® for opioid overdose emergencies, addressing a critical public health challenge posed by the opioid crisis. Paul Williams from Emergent emphasized their commitment to enhancing access to lifesaving treatments like NARCAN®, which works quickly to reverse opioid overdoses. The product is notable for being the only 4 mg intranasal naloxone spray in Canada with a four-year shelf life. This new standing offer follows a previous five-year agreement set to expire in September 2026.
Potential Positives
- Emergent BioSolutions has been awarded a significant standing offer by the Government of Canada to supply NARCAN® Nasal Spray, reinforcing its role in addressing the opioid crisis in Canada.
- The standing offer allows for enhanced access to NARCAN® Nasal Spray across federal, provincial, and territorial organizations in Canada, potentially saving lives and improving public health outcomes.
- The standing offer is effective for three years with an option to extend for two more years, providing a stable revenue stream and long-term partnership with the Government of Canada.
- NARCAN® Nasal Spray, being the only 4 mg, intranasal naloxone spray in Canada with a four-year shelf life, positions Emergent BioSolutions as a leader in effective opioid overdose response solutions.
Potential Negatives
- While the standing offer signifies a continued partnership with the Government of Canada, it highlights the ongoing crisis surrounding opioid overdoses, which reflects negatively on the overall public health environment and the company's position in addressing this urgent issue.
- The mention of a competitive procurement process suggests that Emergent BioSolutions faced competition, which could indicate that their product may not be the sole or preferred choice in the market.
- The press release emphasizes the need for public health preparedness for opioid overdoses, potentially suggesting that there are significant shortcomings in current public health responses that Emergent's products are attempting to address.
FAQ
What is the significance of the standing offer for NARCAN® Nasal Spray?
The standing offer expands access to opioid overdose emergency treatment across Canada, supporting timely access to life-saving medication in communities.
How long is the standing offer for NARCAN® Nasal Spray effective?
The standing offer is effective from October 1, 2026, to September 30, 2029, with an option to extend for two additional years.
Who can procure NARCAN® Nasal Spray under the standing offer?
Authorized federal departments, agencies, Crown corporations, provinces, territories, and other designated public sector organizations can procure NARCAN® Nasal Spray.
What is NARCAN® Nasal Spray used for?
NARCAN® Nasal Spray is used to reverse the effects of opioid overdose, providing emergency treatment for known or suspected cases.
Who is Emergent BioSolutions?
Emergent BioSolutions is a company focused on protecting public health by providing life-saving solutions for health threats, including opioid overdose emergencies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EBS Insider Trading Activity
$EBS insiders have traded $EBS stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $EBS stock by insiders over the last 6 months:
- KATHRYN C ZOON has made 0 purchases and 2 sales selling 17,202 shares for an estimated $144,453.
- DONALD W DEGOLYER has made 0 purchases and 2 sales selling 15,481 shares for an estimated $129,993.
- KEITH KATKIN sold 15,481 shares for an estimated $128,182
- SUJATA TYAGI DAYAL has made 0 purchases and 2 sales selling 13,761 shares for an estimated $115,610.
- PAUL ANTHONY WILLIAMS (SVP, Products Business) has made 0 purchases and 2 sales selling 7,000 shares for an estimated $58,960.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$EBS Revenue
$EBS had revenues of $234.3M in Q2 2026. This is an increase of 2110.38% from the same period in the prior year.
You can track EBS financials on Quiver Quantitative's EBS stock page.
You can access data on EBS stock through the Quiver Quantitative API.
$EBS Hedge Fund Activity
We have seen 101 institutional investors add shares of $EBS stock to their portfolio, and 99 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,200,791 shares (+inf%) to their portfolio in Q2 2026, for an estimated $10,062,628
- LSV ASSET MANAGEMENT added 799,151 shares (+89.1%) to their portfolio in Q2 2026, for an estimated $6,696,885
- PALISADE CAPITAL MANAGEMENT, LP removed 750,707 shares (-59.3%) from their portfolio in Q2 2026, for an estimated $6,290,924
- MARSHALL WACE, LLP removed 577,734 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $4,841,410
- MILLENNIUM MANAGEMENT LLC added 540,184 shares (+101.5%) to their portfolio in Q2 2026, for an estimated $4,526,741
- RUSSELL INVESTMENTS GROUP, LTD. added 523,584 shares (+155.9%) to their portfolio in Q2 2026, for an estimated $4,387,633
- BLACKROCK, INC. added 375,137 shares (+8.6%) to their portfolio in Q2 2026, for an estimated $3,143,648
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
-
Standing offer expands access to opioid overdose emergency treatment across participating federal, provincial and territorial organizations in Canada
WINNIPEG, Manitoba, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply NARCAN® Nasal Spray. The standing offer is effective from October 1, 2026, through September 30, 2029, with an option to extend for an additional two years.
Under the standing offer, authorized federal departments, agencies, Crown corporations, provinces, territories and other designated public sector organizations across Canada may procure NARCAN® Nasal Spray through individual call-ups, helping support timely access to overdose reversal medication in communities nationwide.
"Canada continues to face a significant public health challenge from the opioid crisis and expanding access to naloxone remains a critical component of overdose response efforts," said Paul Williams, head of products business, global government & public affairs at Emergent. "We are proud that the Government of Canada has selected NARCAN® Nasal Spray under this standing offer, reinforcing our commitment to helping to protect and save lives."
NARCAN ® Nasal Spray is designed to reverse the effects of an opioid poisoning in minutes and is the only 4 mg, intranasal naloxone spray in Canada with a shelf life of four years (48 months). This award follows an existing 5-year standing offer between Emergent and the Government of Canada set to expire in September 2026.
"As communities across Canada continue efforts to prevent opioid poisoning deaths, we remain focused on ensuring broad availability of NARCAN® Nasal Spray and supporting public health preparedness," added Danielle Portnik, vice president and general manager at Emergent. "We appreciate the opportunity to continue working with the Government of Canada to improve access to this lifesaving treatment."
About NARCAN® Nasal Spray
NARCAN ® Nasal Spray is a pure opioid antagonist indicated for emergency use to reverse known or suspected opioid overdose, as manifested by respiratory and/or severe central nervous system depression.
While NARCAN ® Nasal Spray can be administered by a non-health care professional, it is not intended to be a substitute for professional medical care. Always call 911 as soon as an opioid overdose is suspected, before administering NARCAN ® Nasal Spray.
Always read the label and follow the directions for use.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our
website
and follow us on
LinkedIn
,
X
,
Instagram
,
Apple Podcasts
and
Spotify
.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the availability and Canadian government procurement of NARCAN® Nasal Spray are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
[email protected]
Media Contact:
Assal Hellmer
Vice President, Communications
[email protected]
